Travere Therapeutics to Present at Upcoming Investor Conferences
February 08, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
August 22, 2022 07:00 ET
|
Travere Therapeutics, Inc.
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...
Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 28, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
May 16, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
December 15, 2021 07:00 ET
|
Travere Therapeutics, Inc.
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
September 07, 2021 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
November 16, 2020 08:00 ET
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...